GlassScriptPhysician profile
Katie Skutvik
NPI 1720726359
$1,183.88
in general payments reported to CMS, 2019-2025
19 companies · $38.01 in 2025
The $38.01 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $244 · 2023: $480 · 2024: $422 · 2025: $38.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730 · Honoraria: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.88 |
| Honoraria | $210.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $210.00 | 2023 | |
| Astellas Pharma US INC | $143.46 | 2022-2023 | Xospata |
| Merck Sharp & Dohme LLC | $121.45 | 2023-2024 | Dificid, Prevymis, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $103.44 | 2022-2024 | Iclusig, Ninlaro |
| Daiichi Sankyo INC. | $94.07 | 2023-2024 | Vanflyta |
| Jazz Pharmaceuticals INC. | $82.67 | 2023-2024 | |
| Incyte Corporation | $71.37 | 2022-2024 | Pemazyre, Monjuvi |
| Sobi, INC | $54.07 | 2024 | |
| Seagen INC. | $44.49 | 2023 | Adcetris |
| Emd Serono, INC. | $39.79 | 2024 | |
| Pfizer INC. | $38.01 | 2025 | |
| Genentech USA, INC. | $30.27 | 2023 | Venclexta |
| Amgen INC. | $28.00 | 2022 | |
| Genmab U.S., INC. | $25.84 | 2023 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.89 | 2022 | |
| Janssen Biotech, INC. | $19.20 | 2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $18.13 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.85 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Skutvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.